Samsung Life Public Welfare Foundation

Medipost Co., Ltd

Encell Co., Ltd.

Chong Kun Dang Pharmaceutical Corporation

Jong Wook Chang

Yoon-Sun Yang

Duk Lyul Na

Hyo Jin Son

Won Il Oh

Soo Jin Choi

Wonil Oh

Ju-Yeon Kim

Ji Hyun Kim

Jong Hyun Kim

Hong Bae Jeon

Sun-Young Jeong

Dal-Soo Kim

Dal Soo Kim

Byung-Ok Choi

Hyeong Seop Kim

Shin Ji Oh

Sang Eon Park

Su Hyeon Myeong

Sung Jun Kang

Won Ii Oh

Ju Yeon Kim

Yoon Sun Yang

Kyoung Woo Lee

Seung Kee Moon

The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

Pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells

Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.

Producing method of mesenchymal stem cell for prevention or treatment of brain neuronal disease including ghrelin treatment and use thereof

The present disclosure relates to a medium composition for enhancing proliferation of stem cells, comprising ethionamide, and a use thereof. It is possible, according to the present disclosure, to mass-produce highly-efficient next-generation stem cells through a simple and safe method of controlling a culturing environment, without using genetic modification or viral vectors, etc.

Method for enhancing proliferation capability of stem cells using ethionamide

The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.

Method of reinforcing efficacy of stem cells using ethionamide

The present invention relates to a medium composition for improving stem cell migration, which includes ethionamide, and a use thereof. According to the present invention, the migration of stem cells may be effectively improved by the adjustment of a culture environment, which is a simple and safe method, without using gene manipulation or a viral vector, and the stem cells improved in migration by the method may be effectively used as a stem cell therapeutic agent that is able to function by rapidly migrating to the damaged region after transplantation.

Method for improving stem cell migration using ethionamide

Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.

Composition comprising a culture solution of mesenchymal stem cells for the treatment of neural diseases

A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases.

Administering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury

Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells

The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a fragment or a variant thereof as an active ingredient, which can increase the expression of neprilysin to remove amyloid-beta (A&#x3b2;), a cause of dementia, and is thus useful in preventing or treating a neurological disease including Alzheimer's disease.

Use of ICAM-1 for prevention or treatment of neurological diseases

Provided is a gene therapy composition for transferring one of a therapeutic gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8 (IL-8) or GRO-&#x3b1; and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-&#x3b1;, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs.

UCB-MSCs comprising a tumor suppressor gene reduce the size of an IL-8 or GRO-&#x3b1;expressing tumor

Growing community of inventors

Seoul, South Korea

Jong Wook Chang